Christopher Staral

Revance Therapeutics Inc (NASDAQ: RVNC) has dropped 9 percent since the start of the year, but it's begun a path to redemption through a new, respected advocate. The Rating Goldman Sachs analysts Dana Flanders and Christopher Staral initiated coverage on Revance with a Buy rating and a $60...

Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...